Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
Figure 4
Effect of lenalidomide on the proliferation of T cell subsets. (a) The histograms show the CFSE expression of CD4 T cells, CD8 T cells, and NKT-like cells before and after stimulation with lenalidomide. PBMCs were labeled with CFSE and cultured with 1 μM lenalidomide or DMSO for 14 days. CFSE expression in CD4 T cells (CD3+CD4+), CD8 T cells (CD3+CD8+), and NKT-like cells (CD3+CD8+CD56+) was examined by flow cytometry. One representative CLL patient and one donor are shown. (b) The figure shows the compilation of the results obtained from CLL patients () and donors (). Results are expressed as the fold induction of the percentage of proliferative CD4 T cells, CD8 T cells, and NKT-like cells of lenalidomide-treated cells relative to the vehicle-treated control. (; ; , Mann-Whitney U test).
